Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

This study has been completed.
Information provided by:
Baxalta US Inc. Identifier:
First received: October 29, 2008
Last updated: April 21, 2016
Last verified: October 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2007
  Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)